vs
Side-by-side financial comparison of GRID DYNAMICS HOLDINGS, INC. (GDYN) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $104.1M, roughly 1.2× GRID DYNAMICS HOLDINGS, INC.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 3.7%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 12.0%).
Escape Dynamics, Inc. was a Colorado-based technology company that operated 2010–2015 focused on bringing to market single-stage-to-orbit reusable electromagnetically powered spaceplanes.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
GDYN vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $104.1M | $129.7M |
| Net Profit | $-1.5M | — |
| Gross Margin | 34.8% | 98.0% |
| Operating Margin | 61.7% | -25.0% |
| Net Margin | -1.4% | — |
| Revenue YoY | 3.7% | 73.4% |
| Net Profit YoY | -150.6% | — |
| EPS (diluted) | $-0.02 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.1M | — | ||
| Q4 25 | $106.2M | $129.7M | ||
| Q3 25 | $104.2M | $164.9M | ||
| Q2 25 | $101.1M | $114.4M | ||
| Q1 25 | $100.4M | $81.7M | ||
| Q4 24 | $100.3M | $74.8M | ||
| Q3 24 | $87.4M | $62.9M | ||
| Q2 24 | $83.0M | $54.1M |
| Q1 26 | $-1.5M | — | ||
| Q4 25 | $306.0K | — | ||
| Q3 25 | $1.2M | $25.7M | ||
| Q2 25 | $5.3M | $-12.8M | ||
| Q1 25 | $2.9M | $-41.2M | ||
| Q4 24 | $4.5M | — | ||
| Q3 24 | $4.3M | $-54.8M | ||
| Q2 24 | $-817.0K | $-70.4M |
| Q1 26 | 34.8% | — | ||
| Q4 25 | 34.0% | 98.0% | ||
| Q3 25 | 33.3% | 99.0% | ||
| Q2 25 | 34.1% | 98.7% | ||
| Q1 25 | 36.8% | 94.3% | ||
| Q4 24 | 36.9% | 96.6% | ||
| Q3 24 | 37.4% | 97.4% | ||
| Q2 24 | 35.6% | 96.2% |
| Q1 26 | 61.7% | — | ||
| Q4 25 | 0.5% | -25.0% | ||
| Q3 25 | -0.2% | 15.1% | ||
| Q2 25 | -0.1% | -11.1% | ||
| Q1 25 | -2.0% | -52.2% | ||
| Q4 24 | 1.3% | -81.2% | ||
| Q3 24 | 2.4% | -89.3% | ||
| Q2 24 | 0.0% | -125.1% |
| Q1 26 | -1.4% | — | ||
| Q4 25 | 0.3% | — | ||
| Q3 25 | 1.1% | 15.6% | ||
| Q2 25 | 5.2% | -11.1% | ||
| Q1 25 | 2.9% | -50.4% | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 4.9% | -87.1% | ||
| Q2 24 | -1.0% | -130.1% |
| Q1 26 | $-0.02 | — | ||
| Q4 25 | $0.01 | $0.04 | ||
| Q3 25 | $0.01 | $0.28 | ||
| Q2 25 | $0.06 | $-0.14 | ||
| Q1 25 | $0.03 | $-0.47 | ||
| Q4 24 | $0.06 | $-0.71 | ||
| Q3 24 | $0.05 | $-0.70 | ||
| Q2 24 | $-0.01 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $327.5M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $530.1M | $114.8M |
| Total Assets | $605.0M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $327.5M | — | ||
| Q4 25 | $342.1M | $93.0M | ||
| Q3 25 | $338.6M | $110.9M | ||
| Q2 25 | $336.8M | $75.2M | ||
| Q1 25 | $325.5M | $61.9M | ||
| Q4 24 | $334.7M | $58.5M | ||
| Q3 24 | $231.3M | $36.4M | ||
| Q2 24 | $256.0M | $32.3M |
| Q1 26 | $530.1M | — | ||
| Q4 25 | $542.1M | $114.8M | ||
| Q3 25 | $537.7M | $73.6M | ||
| Q2 25 | $532.2M | $32.7M | ||
| Q1 25 | $517.4M | $32.8M | ||
| Q4 24 | $517.8M | $59.1M | ||
| Q3 24 | $400.2M | $-30.5M | ||
| Q2 24 | $388.4M | $15.1M |
| Q1 26 | $605.0M | — | ||
| Q4 25 | $612.9M | $605.2M | ||
| Q3 25 | $613.2M | $538.6M | ||
| Q2 25 | $608.9M | $555.3M | ||
| Q1 25 | $590.9M | $548.8M | ||
| Q4 24 | $592.2M | $594.1M | ||
| Q3 24 | $477.3M | $504.4M | ||
| Q2 24 | $443.6M | $551.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $9.9M | $60.7M | ||
| Q3 25 | $7.0M | $14.3M | ||
| Q2 25 | $14.4M | $5.0M | ||
| Q1 25 | $9.4M | $-42.2M | ||
| Q4 24 | $7.1M | $-35.7M | ||
| Q3 24 | $9.2M | $-42.5M | ||
| Q2 24 | $10.7M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | $6.1M | — | ||
| Q3 25 | $2.9M | $14.2M | ||
| Q2 25 | $10.2M | — | ||
| Q1 25 | $6.0M | — | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $5.9M | — | ||
| Q2 24 | $8.0M | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | — | ||
| Q3 25 | 2.8% | 8.6% | ||
| Q2 25 | 10.1% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 9.7% | -74.5% |
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.9% | 0.1% | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 3.7% | 0.0% | ||
| Q2 24 | 3.2% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 32.34× | — | ||
| Q3 25 | 5.92× | 0.56× | ||
| Q2 25 | 2.73× | — | ||
| Q1 25 | 3.21× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GDYN
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
